Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity (SulfoTDAH)
ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.
연구 개요
상세 설명
This is a randomised controlled trial with a double-blind control group. The aim is to test the efficacy of Sulforaphane versus placebo by comparing these two groups with a 1:1 ratio.
The primary objective is to evaluate the efficacy of sulforaphane treatment versus placebo on the total inattention and hyperactivity/impulsivity score measured by the ADHD-RS scale (parents) at 8 weeks in children aged 6 to 12 years suffering from ADHD.
The primary endpoint was the ADHD-RS parent inattention and hyperactivity/impulsivity score at 8 weeks.
Secondary objectives:
To assess the efficacy of sulforaphane treatment versus placebo at 2, 4 and 8 weeks in children aged 6-12 years with ADHD on:
- Inattention and hyperactivity/impulsivity symptoms assessed by parents using the ADHD-RS;
- Social interactions using the SRS scale (Social Responsiveness Scale);
- Emotional dysregulation using the SDQ (Strength and Difficulties Questionnaire);
- Global functioning using the CGI-S (Clinical Global Impression - Severity) and the CGI-I (Clinical Global Impression - Improvement).
To assess the effect of treatment with sulforaphane versus placebo on attention and inhibition at 4 and 8 weeks: using a specific neuropsychological assessment: CPT (Continuous Performance Test); symptoms of inattention and hyperactivity/impulsivity assessed by the teacher using the ADHD-RS self-questionnaire. Differences in behaviour may be observed depending on the context (school versus family). It is therefore important to have 2 sources of information for the ADHD-RS questionnaire: the parents and the teacher.
To assess the tolerability of treatment with sulforaphane from a clinical point of view (use of a PAERS (Paediatrician Adverse Events Rating Scale) and a biological point of view (blood count, AST, ALT, total and conjugated bilirubin, blood ionogram, urea, creatininemia, T4, TSH).
The subgroup of patients included in the Robert Debré Hospital will have a High Resolution Electroencephalogram (HR-EEG) in order to study the electroencephalographic markers of response to treatment with sulforaphane.
An interview to assess interest in and satisfaction with the treatment will be conducted with the parents (Robert Debré) and the child in the month following the end of the study as part of a qualitative study.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Eric ACQUAVIVA, PhD
- 전화번호: +33 0140034092
- 이메일: eric.acquaviva@aphp.fr
연구 장소
-
-
-
Paris, 프랑스, 75019
- 모병
- Robert Debre Hospital
-
연락하다:
- Eric ACQUAVIVA, MD, PhD
- 전화번호: +3340034092
- 이메일: eric.acquaviva@aphp.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Children aged 6 to 12
- Diagnosis of ADHD according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)
- Followed or hospitalised in an investigating centre
- Consent of holders of parental authority
- Patient covered by health insurance (social security or CMU)
- Patients able to swallow capsules
Exclusion Criteria:
- Allergy to broccoli
- Psychotropic treatment including methylphenidate in the month prior to inclusion
- Ongoing psychotherapeutic and/or psycho-educational treatment specific to ADHD
- ASD (Autism Spectrum Disorder) according to DSM-5 criteria, intellectual disability (IQ< 80)
- Chronic neurological disease, epilepsy
- Holders of parental authority under guardianship or curatorship
- Previous intake of sulforaphane
- Known hypothyroidism or current thyroid treatment
- Participation in other interventional research involving the human person or being within the exclusion period following previous research involving the human person, where applicable
- Patient under AME (state medical aid)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Sulforaphane
Prostaphane® is a dietary supplement based on SULFODYNE®, a broccoli seed extract standardised in free, stabilised sulforaphane. Patients will receive treatment for 8 weeks at the following dosage:
Each capsule contains 10mg of Sulforaphane. |
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane |
|
위약 비교기: Placebo
Patients will receive treatment for 8 weeks at the following dosage:
Each capsule contains placebo. |
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Inattention scores in ADHD-RS parents
기간: 8 weeks
|
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
8 weeks
|
|
Hyperactivity/impulsivity scores in ADHD-RS parents
기간: 8 weeks
|
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
8 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Inattention scores in ADHD-RS parents
기간: 2, 4 and 12 weeks
|
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
2, 4 and 12 weeks
|
|
Hyperactivity/impulsivity scores in ADHD-RS parents
기간: 2, 4 and 12 weeks
|
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
2, 4 and 12 weeks
|
|
Social Responsiveness Scale (SRS) scores and sub-scores
기간: 4, 8 and 12 weeks
|
Social Responsiveness Scale (SRS) scores and sub-scores |
4, 8 and 12 weeks
|
|
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score
기간: 2, 4, 8 and 12 weeks
|
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score |
2, 4, 8 and 12 weeks
|
|
Sustained attention and inhibition scores in the CPT (Continuous Performance Test)
기간: 4 and 8 weeks
|
Sustained attention and inhibition scores in the CPT (Continuous Performance Test) |
4 and 8 weeks
|
|
CGI-S (Clinical Global Impression - Severity) score
기간: 4 and 8 weeks
|
CGI-S (Clinical Global Impression - Severity) score |
4 and 8 weeks
|
|
CGI-I (Clinical Global Impression - Improvement) score
기간: 4 and 8 weeks
|
CGI-I (Clinical Global Impression - Improvement) score |
4 and 8 weeks
|
|
ADHD-RS teacher inattention and hyperactivity/impulsivity scores
기간: 4 and 8 weeks
|
ADHD-RS teacher inattention and hyperactivity/impulsivity scores |
4 and 8 weeks
|
|
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)
기간: 4 and 8 weeks
|
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale) |
4 and 8 weeks
|
|
tolerance of treatment: Blood sample: Blood count
기간: 8 weeks
|
tolerance of treatment: Blood sample: Blood count |
8 weeks
|
|
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)
기간: 8 weeks
|
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase) |
8 weeks
|
|
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)
기간: 8 weeks
|
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase) |
8 weeks
|
|
tolerance of treatment: Blood sample: total bilirubin
기간: 8 weeks
|
tolerance of treatment: Blood sample: total bilirubin |
8 weeks
|
|
tolerance of treatment: Blood sample: conjugated bilirubin
기간: 8 weeks
|
tolerance of treatment: Blood sample: conjugated bilirubin |
8 weeks
|
|
tolerance of treatment: Blood sample: ionogram
기간: 8 weeks
|
tolerance of treatment: Blood sample: ionogram |
8 weeks
|
|
tolerance of treatment: Blood sample: urea
기간: 8 weeks
|
tolerance of treatment: Blood sample: urea |
8 weeks
|
|
tolerance of treatment: Blood sample: creatinine
기간: 8 weeks
|
tolerance of treatment: Blood sample: creatinine |
8 weeks
|
|
tolerance of treatment: Blood sample: T4
기간: 8 weeks
|
tolerance of treatment: Blood sample: T4 |
8 weeks
|
|
tolerance of treatment: Blood sample: TSH
기간: 8 weeks
|
tolerance of treatment: Blood sample: TSH |
8 weeks
|
|
Robert Debré patients: EEG-HR (High Resolution Electroencephalogram)
기간: 4 and 8 weeks
|
the criterion used will be the theta-beta ratio. |
4 and 8 weeks
|
|
Robert Debré patients: qualitative study:
기간: one month post treatment
|
The exploration criterion will be an in-depth description of the experience of the families and the child with regard to treatment with sulforaphane (interest and satisfaction). |
one month post treatment
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- APHP230862
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .